Advanced and recurrent endometrial carcinoma (EC) exhibits a poor response to chemotherapy and low survival rates. It has been previously reported that human prolactin (hPRL) is upregulated in endometrial cancer and is associated with worse survival outcomes. We provide evidence for the functional role of hPRL in EC progression. We generated a model for the study of autocrine hPRLmediated cell functional effects through the forced expression of hPRL in human EC cells. Autocrine hPRL expression stimulated cell proliferation, anchorage-independent growth, migration, and invasion of EC cells and promoted tumor growth, local invasion, and metastatic colonization in xenograft models. In addition, forced expression of hPRL decreased sensitivity of EC cells to chemotherapeutic drugs (i.e., doxorubicin and paclitaxel), both in vitro and in vivo. Consistently, small interfering RNA-mediated depletion of hPRL significantly reduced oncogenicity and enhanced the chemosensitivity of EC cells. As CD24 is hPRL-regulated and has been implicated in drug resistance in EC, we further showed that CD24 is a critical mediator of hPRL-stimulated reduced sensitivity to doxorubicin and paclitaxel in EC cells. Therefore, inhibition of hPRL signaling is a potential therapeutic strategy for the treatment of late-stage EC, which can be used in combination with chemotherapy to improve the chemotherapeutic response. (Endocrinology 158: 1595(Endocrinology 158: -1611(Endocrinology 158: , 2017 E ndometrial carcinoma (EC) remains the most common malignancy of the female genital tract (1). Although early-stage (stage I or II) EC cases are treated by hysterectomy and radiotherapy with a favorable prognosis, late-stage (stage III or IV) or recurrent EC invariably exhibits a poor prognosis, with a median survival time of ,1 year (2, 3). Hysterectomy, together with a combination of chemotherapy and radiotherapy, is commonly used as the standard treatment for patients with advanced and recurrent EC (3). The chemotherapeutic agents (taxanes, anthracyclines, and platinum agents) yield response rates of .20% when used as a single agent and 40% to 50% when used in combination to treat advanced and recurrent EC (3). Furthermore, adjuvant chemotherapy has been reported to provide survival benefits in stage III EC (3). However, these chemotherapeutic regimens are not curative, and patients with late-stage EC tend to develop therapeutic resistance and experience disease recurrence (4). This reinforces the need to identify novel oncogenic *These authors contributed equally to this study. Abbreviations: 3D, three-dimensional; BrdU, 5-bromo-2-deoxyuridine; EC, endometrial carcinoma; GH, growth hormone; hPRL, human prolactin; IC 50 , half maximal inhibitory concentration; mRNA, messenger RNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; PBS, phosphate-buffered saline; PRL, prolactin; PRLR, prolactin receptor; qPCR, quantitative polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction; siRNA, small interfering RNA; TUNEL, terminal transferase deoxyuridine triphosphate nick end labeling.
therapeutic targets involved in EC that can be used in combination with chemotherapeutic agents to improve the chemotherapy response and prognosis of late-stage and recurrent EC (4) .
Human prolactin (hPRL), belonging to the prolactin (PRL)/growth hormone (GH)/placental lactogen family, is a polypeptide hormone secreted by the pituitary gland with classic endocrine functions (5, 6) . In addition, hPRL is secreted from extrapituitary sites, including the mammary glands and endometrium, where it acts locally as a growth factor (5, 6) . hPRL is physiologically involved in mammary gland development, lactation, implantation, and pregnancy (5, 6) . Studies have provided increasing evidence for the involvement of autocrine/paracrine hPRL in several cancers, such as mammary, prostate, hepatocellular, ovarian, and endometrial carcinoma (5, (7) (8) (9) (10) (11) (12) (13) (14) . Serum hPRL has also been reported to serve as a sensitive and specific biomarker for the early detection of EC, and the combination of serum hPRL with other biomarkers further improves the accuracy and selectivity of the EC diagnosis (13) . Another study reported elevated serum levels of hPRL in EC and demonstrated that exogenous hPRL stimulates proliferation and inhibits cisplatininduced apoptosis in EC cells (5) . More recently, our group observed that hPRL expression, individually or combined with expression of human GH, correlates with stage and myometrial invasion and is associated with worse relapse-free survival and overall survival in EC patients (12) . However, the functional roles of autocrine hPRL in EC have not been fully elucidated. hPRL has also been implicated in chemotherapeutic resistance in breast and prostate cancers (15) (16) (17) (18) (19) , suggesting the possible involvement of hPRL in modulating chemosensitivity and/or chemoresistance in EC.
CD24 is a small, heavily glycosylated, glycosylphosphatidylinositol-anchored membrane protein that is widely expressed on hematopoietic cells, including B cell precursors, T cells, neutrophils, neural cells, and epithelial cells (20) . CD24 is involved in diverse functions, acting as a marker for differentiation in hematopoietic and neuronal cells, as a modulator of the adaptive immune response, and as a cell adhesion molecule (20) . Overexpression of CD24 has been reported in various cancers, including EC (21, 22) . Ectopic CD24 expression was demonstrated to promote oncogenesis, tumor development, and metastasis of human cancers (4, 23, 24) . Furthermore, elevated expression of CD24 is a prognostic indicator of poor survival in lung, prostate, mammary, and ovarian carcinoma (22, 25, 26) . CD24 was also documented to result in resistance to antitumor drugs, including cisplatin, doxorubicin, and paclitaxel in ovarian cancer and EC (4, 27) . CD24 is a hPRL-regulated gene (28) ; however, the role of CD24 in hPRL-mediated behavior of EC has not been well-defined.
In the present study, we have defined a functional role for autocrine hPRL in EC. We have demonstrated that forced expression of hPRL in EC cells promotes cell proliferation, anchorage-independent cell growth, migration, and invasion in vitro and increases tumor development and metastasis in vivo. Furthermore, we have shown that autocrine hPRL reduces the sensitivity of EC cells toward doxorubicin and paclitaxel, which are chemotherapeutic agents commonly used for late-stage EC (29) . Concordantly, we observed that depletion of hPRL reduces oncogenicity and increases sensitivity of the EC cells to doxorubicin and paclitaxel. Therefore, autocrine hPRL is a potential therapeutic target in EC, and antagonists to hPRL could be used in combination with chemotherapy to improve the chemotherapeutic response.
Materials and Methods

Materials
Doxorubicin and paclitaxel were purchased from SigmaAldrich (Auckland, New Zealand). Doxorubicin was dissolved in phosphate-buffered saline (PBS) at a stock concentration of 1 mmol/L. Paclitaxel was dissolved in dimethyl sulfoxide at a stock concentration of 1 mmol/L.
Cell lines and cell culture
The human EC cell lines, Ishikawa and RL95-2, were obtained from the American Type Culture Collection (Rockville, MD) and cultured in conditions, as recommended. All cells were maintained in a humidified incubator at 37°C and 5% carbon dioxide.
Plasmid constructs
The hPRL coding sequence transcript variant 1 (GenBank accession no. NM_000948) was cloned into the mammalian expression vector pIRESneo3 (Thermo Fisher Scientific Life Sciences, Waltham, MA), and the construct was designated pIRESneo3-hPRL.
Generation of stable cell lines
Ishikawa and RL95-2 cells were stably transfected with pIRESneo3 vector (designated as Ishikawa-Vec and RL95-2-Vec cells) or pIRESneo3-hPRL plasmid (designated as IshikawahPRL and RL95-2-hPRL cells) using Attractne (Qiagen, Hilden, Germany). Positive cell clones gained antibiotic resistance and were selected by G418 (Sangon, Shanghai, China), as previously described (30) . The increased expression of hPRL in the stably transfected cell lines was determined by reverse transcription polymerase chain reaction (RT-PCR) and Western blot.
Transfection of small interfering RNA
Ishikawa or RL95-2 cells were seeded in six-well plates and transfected with hPRL-small interfering RNA (siRNA), CD24-siRNA (GenePharma, Shanghai, China), or scrambled-siRNA (negative control) using Hiperfect (Qiagen), following the manufacturer's protocol. The cells were harvested in TRIzol (Thermo Fisher Scientific, Waltham, MA) for RNA extraction 48 hours after transfection, and in radioimmunoprecipitation assay lysis buffer for protein extraction 72 hours after transfection. The siRNAs used were as follows: hPRL siRNA (target 714-735: CAGCGAAUUCGAUAAACGGUATT), CD24 siRNA (target 171-189: CCCACGCAGAUUUAUUCCATT; GenePharma).
RT-PCR and quantitative polymerase chain reaction
Total RNA was isolated from cells using the TRIzol Plus RNA Purification system (Thermo Fisher Scientific Life Sciences), as previously described (4) . RNA samples were further treated with DNase I (Fermentas; Thermo Fisher Scientific) for 30 minutes at 37°C. Total RNA was then converted to complementary DNA using SuperScript III Reverse transcriptase (Thermo Fisher Scientific). Ordinary Taq Kit (TaKaRa, Tokyo, Japan) was used for PCR, and SYBR Premix Ex Taq Kit (TaKaRa) was used for quantitative polymerase chain reaction (qPCR). The primers for hPRL were as follows: forward 5 0 -GGGTTCATTACCAAGGCCATC-3 0 ; reverse 5 0 -TTCAG-GATGAACCTGGCTGAC-3 0 (276 bp). The primers for CD24 were as follows: forward 5 0 -CCAACTAATGCCACCACCA-3 0 ; reverse 5 0 -GACGTTTCTTGGCCTGAGTC-3 0 (118 bp). The primer sequences of other genes in the qPCR analysis are listed in Supplemental Table 1 .
Western blot analysis
Western blot analysis was performed as previously described (31) . The hPRL antibody used was rabbit anti-hPRL (National Institute of Diabetes and Digestive and Kidney Diseases, AFP10777D, 1:5000).
Cell function assays
Biological assays to determine cell death, proliferation, and oncogenicity, including total cell number assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, 5-bromo-2-deoxyuridine (BrdU) incorporation assay, terminal transferase deoxyuridine triphosphate nick end labeling (TUNEL) immunostaining, anchorage-independent growth (soft agar colony formation assay), three-dimensional (3D) Matrigel growth assay, and in vitro cell motility assays (migration, invasion, and wound healing) were all performed as previously described (30) . The cell cycling kit-8 (Dojindo Molecular Technologies, Rockville, MD) was used to quantify the 3D cell growth. Colony scattering assays were performed as previously reported (32) . The half maximal inhibitory concentration (IC 50 ) values of doxorubicin or paclitaxel in the EC cells were determined using the MTT assay after a 72-hour drug exposure period.
Scanning laser confocal microscopy
Cells grown on sterile cover glass slides were fixed with 4% paraformaldehyde for 20 minutes, permeabilized with 0.1% Triton X-100 in PBS for 3 minutes, and incubated with rhodamine-phalloidin and 4 0 ,6-diamidino-2-phenylindole for 30 minutes. The cellular cytoskeleton and distribution of actin filaments were examined under a laser scanning confocal microscope.
Xenograft analyses
Ishikawa-Vec and Ishikawa-hPRL cells were resuspended in PBS (400 3 10 4 cells/125 mL/site) and injected subcutaneously into 4-week-old female BALB/c nu/nu mice (Shanghai Slaccas Co., Shanghai, China). Tumor formation was observed after approximately 1 week. The tumor sizes were measured every 4 days. Histological analyses with hematoxylin and eosin and TUNEL immunostaining were performed, as previously described (30) . In experiments involving drug treatment, the mice were randomized to receive paclitaxel (10 mg/kg), doxorubicin (5 mg/kg), or PBS (intraperitoneally) once a week, about 15 days after implantation when the tumors had reached approximately 100 mm 3 . Each group consisted of six mice. The tumor sizes were measured every 4 days. For tail vein injection, IshikawaVec and Ishikawa-hPRL cells (400 3 10 4 cells in 250 mL PBS) were injected directly into the lateral tail vein of 4-week-old female BALB/c-nu/nu mice. Each group consisted of six mice. The mice were killed on day 40. Mice liver and lung tissues were fixed in 10% neutral buffered formalin and embedded in paraffin for histological examination. The experiments were performed according to the institutional animal care and use committee guidelines (available at www.iacuc.org) with local institutional approval.
Immunohistochemistry
Immunohistochemical analysis of paraffin-embedded specimens of Ishikawa-Vec and Ishikawa-hPRL cell-derived tumors in mice was performed using the UltraSensitive-SP kit (MaixinBio, Fuzhou, China) with a mouse monoclonal antibody against Ki67 (Zhongshan Goldenbridge Biotechnology Co, Beijing, China), a marker of cell proliferation.
Flow cytometry
To determine the levels of cell surface CD24, the cells were harvested and incubated with the anti-human CD24 antibody (1:100; BD Biosciences 555428, San Diego, CA) for 25 minutes at room temperature. Cells without antibody incubation and cells incubated with isotype-matched antibodies were used as controls. After incubation, the cells were rinsed three times in PBS and used for flow cytometry analyses performed in triplicate.
Statistical analysis
All experiments were performed at least three times. All numerical data are expressed as the mean 6 standard error of the mean from a representative experiment performed in triplicate. The data were analyzed using an unpaired two-tailed t test in Prism, version 5 (GraphPad, San Diego, CA). The association between autocrine hPRL expression and the incidence of lung metastasis in vivo was analyzed using the x 2 test. P values ,0.05 were considered statistically significant.
Results
Autocrine hPRL stimulates cellular proliferation, survival, and oncogenicity of human EC cells
Human EC cell lines (Ishikawa and RL95-2) were stably transfected with an expression plasmid pIRESneo3 encoding hPRL and designated as Ishikawa-hPRL and RL95-2-hPRL cells, respectively. Control cells were correspondingly transfected with the empty plasmid pIRESneo3 and designated as Ishikawa-Vec and RL95-2-Vec cells. The increased expression of hPRL in Ishikawa-hPRL and RL95-2-hPRL cells compared with Ishikawa-Vec and RL95-2-Vec cells was verified at both the messenger RNA (mRNA) [ Fig. 1(a) ] and protein [ Fig. 1(b) ; top] levels. Forced expression of hPRL also increased hPRL secretion into the conditioned media [ Fig.  1(b) ; bottom). Expression of hPRL was also detected in vector control-transfected EC cell lysate and media, albeit at lower levels than Ishikawa-hPRL or RL95-2-hPRL cells, respectively.
In monolayer culture, the Ishikawa-hPRL and RL95-2-hPRL total cell number increased significantly more than the Ishikawa-Vec and RL95-2-Vec total cell number during an 8-day period in serum-replete media [ Fig. 1(c) ]. In the MTT assay, Ishikawa-hPRL cells exhibited significantly enhanced cell viability compared with Ishikawa-Vec cells in serum-depleted (0.2% fetal bovine serum) medium at 48 hours [Supplemental Fig. 1(A) ]. The cell viability of RL95-2-hPRL, however, increased most significantly compared with RL95-2-Vec cells in media containing 10% fetal bovine serum at 48 hours [Supplemental Fig. 1(C) ]. The increase in total cell number with forced expression of hPRL can be attributed to increased cell cycle progression and/or cell survival. To determine whether autocrine hPRL affects EC cell cycle progression, we assessed entry into the S-phase by examining nuclear incorporation of BrdU. Ishikawa-hPRL and RL95-2-hPRL cells exhibited significantly increased nuclear BrdU incorporation compared with IshikawaVec and RL95-2-Vec cells [ Fig. 1(d) ]. In addition, to determine whether autocrine hPRL modulates cell survival, we performed TUNEL assays, which revealed that Ishikawa-hPRL and RL95-2-hPRL cells contained significantly less apoptotic nuclei than Ishikawa-Vec and RL95-2-Vec cells after serum deprivation for 48 hours [ Fig. 1(e) ].
The capacity for anchorage-independent cell growth is a pivotal characteristic of oncogenically transformed cells (33, 34) . To determine the effect of hPRL on anchorage-independent growth of EC cells, we performed soft agar colony formation assay. Forced expression of hPRL in both Ishikawa and RL95-2 cells significantly enhanced anchorage-independent growth, as indicated by increased colony formation in soft agar [ Fig. 1(f) ].
The 3D growth of the EC cells in Matrigel was also investigated, because the 3D cell culture system more closely mimics the physiological condition and is thus more predictive for in vivo cellular behavior (35) . We next determined the effect of forced expression of hPRL on the expression of genes important for EC cell cycle progression and survival using qPCR (Table 1) . Forced expression of hPRL in Ishikawa cells increased the mRNA levels of CCND1, CDK2, CDK4, CCNE1, and CDC25A, concordant with the observed increase in cell cycle progression (36, 37) . In addition, forced expression of hPRL increased the transcript levels of antiapoptotic BCL-2 and BCL2L1 and decreased the mRNA levels of proapoptotic TP53 and BAX (38, 39) . This is consistent with the increased cell survival observed in IshikawahPRL cells compared with the Ishikawa-Vec cells. Furthermore, the mRNA levels of various signal transduction molecules and transcription factors, namely AKT1, ETS2, ERBB2, and MYC, which have previously been reported to be associated with increased oncogenicity of EC cells (40) (41) (42) (43) , were transcriptionally increased by forced expression of hPRL in Ishikawa cells (Table 1) . Thus, forced expression of hPRL in EC cells regulates the expression of genes involved in cell cycle progression and apoptosis to effect increased proliferation and survival. Therefore, depletion of endogenous hPRL reduced the oncogenic potential of EC cells.
Autocrine hPRL promotes invasion and migration of human EC cells
We next evaluated the effect of autocrine hPRL on cell morphology. Examination of the cellular distribution of actin filaments by laser scanning confocal microscopy revealed that forced expression of hPRL resulted in a mesenchymal phenotype in both Ishikawa and RL95-2 cells, forming more scattered colonies and exhibiting increased accumulation of F-actin at the cell periphery, corresponding to the leading protrusions of the cells [ Fig. 3(a) ]. In contrast, depletion of hPRL yielded EC cells with more epithelial characteristics, forming compact colonies and exhibiting less accumulation of F-actin at the cell periphery [ Fig. 3(a) ]. In colony-scattering assays, we observed a significantly smaller proportion of compact cells and a larger proportion of scattered cells with forced expression of hPRL in both Ishikawa and RL95-2 cells We further determined the effect of forced expression of hPRL on the expression of epithelial-, mesenchymal-, and metastatic-related genes (Table 1) . Although hPRL was observed to promote invasion and migration of EC cells, the classic epithelial-mesenchymal transition gene expression pattern, characterized by upregulation of mesenchymal genes and downregulation of epithelial genes, was not observed with forced expression of hPRL in Ishikawa cells. Nevertheless, the mRNA level of MAP2K1, which was reported to be associated with cell invasion and metastasis in EC (44) , was increased dramatically by forced expression of hPRL in Ishikawa cells.
Autocrine hPRL promotes xenograft growth and metastasis of human EC cells
To Fig. 4(a) ]. The tumors formed by Ishikawa-hPRL cells were more than double the size of the tumors formed by IshikawaVec cells at the end of the experiment. Moreover, although Ishikawa-VEC tumors were well-encapsulated and noninvasive, Ishikawa-hPRL tumors displayed evidence of local invasion, including intravasation [ Fig.  4(b), arrows) .
To determine the effect of hPRL on proliferation and apoptosis within the tumor, we quantified the Ki67-and TUNEL-positive cells, respectively. The Ki67-positive cell population in the Ishikawa-hPRL cell-derived tumors was significantly increased compared with that in the tumors generated by Ishikawa-Vec cells [ Fig. 4(c) ]. TUNEL assay on the tumor sections showed that Ishikawa-hPRL cell-derived tumors contained significantly fewer apoptotic nuclei than tumors formed by Ishikawa-Vec cells [ Fig. 4(d) ].
We also examined the effect of hPRL on metastatic seeding capacity of EC cells in vivo, independent of hPRL influence on cellular invasion. Ishikawa-hPRL and Ishikawa-Vec cells were injected into the venous circulation of female nude mice. After 40 days, lung metastases were observed in 5 of 6 mice injected with Ishikawa-hPRL cells but in only 1 of 6 mice injected with Ishikawa-Vec cells [ Fig. 5(a) and 5(b) ].
Autocrine hPRL reduces sensitivity to doxorubicin and paclitaxel in human EC cells
In addition to being a critical growth factor in human cancers (14) , hPRL has been implicated in chemoresistance (17) . As doxorubicin and paclitaxel are two Cells were seeded on glass cover slips in six-well plates in full serum media and subsequently serum-starved for 48 hours. The percentage of TUNEL-positive (apoptotic) nuclei in Ishikawa-hPRL, Ishikawa-Vec, RL95-2-hPRL, and RL95-2-Vec were determined. (f) Soft agar colony formation assay. Cells were seeded in 0.35% agarose in full medium in six-well plates in triplicate. The colonies formed were counted after incubation for 14 days. (g) 3D Matrigel growth. Ishikawa-hPRL, Ishikawa-Vec, RL95-2-hPRL, and RL95-2-Vec cells were cultured in growth factor reduced Matrigel with serum-replete media. After 10 days, the microscopic images were taken, and cell viability was determined using the cell cycling kit-8. *P , 0.05; **P , 0.01; ***P , 0.001.
common chemotherapeutic agents used in EC (29), we examined the effect of hPRL expression on the sensitivity of the EC cells toward these chemotherapeutic agents (Supplemental Fig. 3 ). The IC 50 values of doxorubicin and paclitaxel in Ishikawa-hPRL cells were nearly twofold greater than those in Ishikawa-Vec cells ( Table 2) . The IC 50 value of doxorubicin in RL95-2-hPRL cells was threefold greater, and that of paclitaxel was nearly twofold greater than the respective IC 50 values in RL95-2-Vec cells (Table 2 ). In contrast, the IC 50 values of doxorubicin and paclitaxel in Ishikawa-sihPRL and RL95-2-sihPRL cells were reduced compared with the values in Ishikawa-siVec and RL95-2-siVec cells, respectively (Table 2) . Hence, autocrine hPRL reduced the sensitivity of EC cells to chemotherapeutic agents.
We next performed soft agar colony formation assays with the -Vec and -hPRL EC cells. According to the IC 50 values of doxorubicin and paclitaxel in the Ishikawa and RL95-2 cells, we used 10 mM doxorubicin and 60 nM paclitaxel for these experiments. EC cells with forced expression of hPRL exhibited increased anchorageindependent growth compared with vector control EC cells. On exposure to either doxorubicin or paclitaxel, colony formation of the EC cells decreased. In the presence of doxorubicin or paclitaxel, Ishikawa-hPRL and RL95-2-hPRL cells maintained increased anchorageindependent growth to a level equal to that of the untreated Ishikawa-Vec and RL95-2-Vec cells [ Fig. 6(a-d) ]. This suggests that autocrine hPRL decreases the response of EC cells to doxorubicin and paclitaxel. In contrast, the depletion of hPRL decreased the colony formation in Ishikawa and RL95-2 cells [Supplemental Fig. 4(A-D) ]. Although chemotherapy decreased the colony number of all cells, the depletion of hPRL further decreased anchorage-independent growth of the EC cells significantly, in addition to the inhibitory effect of the chemotherapeutic agents [Supplemental Fig. 4(A-D) ]. Hence, hPRL depletion increases the response of EC cells to chemotherapeutic agents. In addition, the chemotherapy-mediated fold decrease in colony formation of Ishikawa-hPRL and RL95-2-hPRL cells was lower than that of Ishikawa-Vec and RL95-2-Vec cells, as shown in the tables below each graph in Fig. 6a-d . Therefore, autocrine hPRL decreases the sensitivity of EC cells to doxorubicin and paclitaxel. However, the chemotherapy-mediated fold decrease in colony formation of Ishikawa-sihPRL and RL95-2-sihPRL cells was not greater than that of Ishikawa-siVec and RL95-2-siVec cells [Supplemental Fig. 4(A-D) ]. Although the depletion of endogenous hPRL did not increase the sensitivity of EC cells to doxorubicin and paclitaxel, it decreased the relative colony formation of the Ishikawa and RL95-2 cells in the presence of chemotherapy. We further examined the effect of forced expression of hPRL on tumor sensitivity toward the chemotherapeutic agents in vivo. We implanted Ishikawa-Vec and Ishikawa-hPRL cells into the dorsal flank of female nude mice. Both cell lines formed palpable tumors after ,1 week, and the volume of the tumors reached approximately 100 mm 3 after 15 days. The mice of the two groups were subsequently randomized to receive doxorubicin, paclitaxel, or PBS control, as described in Materials and Methods. The tumor sizes were measured every 4 days. Ishikawa-hPRL cell-derived tumors grew faster than the Ishikawa-Vec cell-derived tumors, as previously described. Both Ishikawa-Vec and IshikawahPRL tumors were sensitive to doxorubicin and paclitaxel, with both drugs inhibiting tumor growth in both groups. Nevertheless, the Ishikawa-hPRL cell-derived tumors maintained significantly increased growth rates and tumor volumes compared with Ishikawa-Vec cellderived tumors in the presence of doxorubicin or paclitaxel (Fig. 7) , indicating that autocrine hPRL expression decreased the response of EC cell-derived xenografts to chemotherapy. The chemotherapy-mediated fold reduction in tumor volume of Ishikawa-hPRL cellderived tumors was lower compared with that of Ishikawa-Vec cell-derived tumors (Fig. 7) . Therefore, autocrine hPRL expression also decreases the sensitivity of EC cell-derived xenografts to chemotherapeutic agents in vivo.
hPRL reduces sensitivity to doxorubicin and paclitaxel in human EC cells through CD24
It has previously been reported that forced expression of CD24 in EC cells stimulated cellular proliferation and oncogenicity (4) . High levels of CD24 have been reported to be associated with progression of EC and indicated a worse patient prognosis (4, 21, 45) . Furthermore, CD24 has been shown to reduce the sensitivity of EC cells to doxorubicin and paclitaxel (4) . Because CD24 is a hPRLregulated gene (28), we examined whether CD24 is regulated and used by hPRL to decrease the chemosensitivity of EC cells. Both the mRNA [ Fig. 8(a) ] and the cell surface expression of CD24 [ Fig. 8(b) ] were increased in Ishikawa-hPRL and RL95-2-hPRL cells compared with Ishikawa-Vec and RL95-2-Vec cells, respectively. Accordingly, depletion of endogenous hPRL in Ishikawa or RL95-2 cells resulted in significantly decreased CD24 at both the mRNA [ Fig. 8(a) ] and the cell surface protein [ Fig. 8(b) ] levels. To determine whether hPRL acts through CD24 to confer reduced sensitivity of EC cells to doxorubicin and paclitaxel, we examined the effects of siRNA-mediated depletion of CD24 in EC cells with forced expression of hPRL on the chemosensitivity of the EC cells (Supplemental Fig. 5 ). Similar to Fig. 6 , forced expression of hPRL reduced the sensitivity to doxorubicin and paclitaxel in both Ishikawa and RL95-2 cells, as indicated by the increased cell viability and anchorage-independent growth of the Ishikawa-hPRL and RL95-2-hPRL cells compared with Ishikawa-Vec and RL95-2-Vec cells in the presence of either chemotherapeutic agent, respectively (Fig. 9) . The depletion of CD24 did not significantly decrease the sensitivity of the Ishikawa-Vec and RL95-2-Vec cells to doxorubicin and paclitaxel. However, the depletion of CD24 specifically decreased the hPRL-mediated reduced sensitivity of Ishikawa and RL95-2 cells to either chemotherapeutic agent, as shown by the reduction Cell viability was measured using the MTT assay after a 72-hour drug exposure period with doxorubicin or paclitaxel, followed by a 24-hour drug-free period.
IC 50 values are presented as the mean 6 standard error of the mean of three independent experiments.
in fold increase of cell viability and anchorage-independent growth of Ishikawa-hPRL and RL95-2-hPRL cells compared with Ishikawa-Vec and RL95-2-Vec cells in the presence of either chemotherapeutic agent (Fig. 9 ). In particular, in the cell viability assays, RL95-2-hPRL cells . Collectively, the hPRL-mediated reduced chemosensitivity in EC cells was at least partially CD24 dependent.
Discussion
The efficacious treatment of late-stage EC remains a major challenge in gynecological oncology. The treatment of late-stage EC generally involves surgery with adjuvant chemotherapy (3, 46) . Although the use of adjuvant chemotherapy improves the progression-free survival of advanced and recurrent EC patients, the overall survival of these patients remains invariably poor (46) . The identification of novel targets for potential targeted therapy that can be used in combination with existing therapy will likely improve survival and decrease the chemotherapeutic side effects in late-stage EC patients (47). Several studies have consistently shown increased hPRL expression in endometrial carcinoma samples compared with normal endometrial controls (5, 12, 13) . We have previously observed low hPRL expression in normal endometrium, which was increased in a graded manner in hyperplastic endometrial tissues and endometrial carcinoma, respectively (12) . In addition, an elevated level of serum hPRL in endometrial carcinoma patients compared with healthy controls has been reported (5). Furthermore, increased serum hPRL levels have been reported to be the strongest diagnostic biomarker of endometrial cancer, with high sensitivity and selectivity (13) . We have further provided functional evidence of the involvement of autocrine hPRL in EC progression. We observed that autocrine hPRL promoted cell proliferation and survival and enhanced the invasive and metastatic capacities of EC cells in vitro and in vivo. It has previously been demonstrated that exogenous hPRL stimulates proliferation and inhibits cisplatin-induced apoptosis of endometrial and ovarian cancer cells (5) . Furthermore, the same study showed that chronic hPRL treatment promotes oncogenic transformation of immortalized endometrial fibroblast and normal ovarian epithelial cells (5) . Our previous study reported that tumor hPRL expression correlates with the International Federation of Gynecology and Obstetrics stage and myometrial invasion in endometrial carcinoma (12) . Furthermore, we observed that hPRL alone or combined with hGH predicts for worse survival outcomes for patients with EC or mammary carcinoma (12) . Elevated serum hPRL levels have been detected in EC patients, suggesting the potential of hPRL as a diagnostic biomarker (5, 13) . In addition to endometrial cancer, autocrine hPRL has been shown to promote survival and migration of ovarian cancer cells, and prolactin receptor (PRLR) antagonists demonstrated inhibitory effects on cell survival and migration, suggestive of a potential therapeutic effect of the PRLR antagonists in ovarian cancer (48) . Moreover, a panel of four serum biomarkers, including hPRL, has been reported to show improved predictability in the diagnosis of early-stage epithelial ovarian cancer (10) . In addition to gynecological cancers, several studies have supported an oncogenic role of hPRL in breast cancer. We have previously shown that the PRLR, which is upregulated by HOXA1, mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells (49) . Several recent studies have provided evidence of the functional role of hPRL in promoting breast cancer cell invasion and migration. hPRL has been reported to regulate actin cytoskeleton remodeling by increasing c-SRC expression and phosphorylation, thereby enhancing breast cancer cell migration (50) . Another group found p21-activated kinase 1 (PAK1) as a downstream mediator of hPRL-mediated breast cancer cell motility and invasion (51, 52 ). An alternative mechanism of hPRL-stimulated breast cancer invasion is dependent on Na + /H + exchanger (NHE1) activity (53) .
Furthermore, hPRL was demonstrated to trigger increased breast cancer cell proliferation and migration through the upregulation of sphingosine kinase 1 expression and activation (54) . The specific knockdown of long PRLR isoform has been shown to inhibit the metastatic spread of breast cancer, in addition to promoting apoptosis of the cancer stem cell population that might be involved in the metastatic process (55) . In addition, hPRL was reported to show a protective effect against C2 ceramide-stimulated apoptosis in breast cancer cell lines (56) . These observations were supported by a recent meta-analysis that reported an association between the plasma hPRL level and an increased risk of postmenopausal, estrogen receptor-positive/progesterone receptor-positive in situ and invasive breast carcinoma (57) . Furthermore, an association of hyperprolactinemia with increased tumor size, higher disease stage, lymph node involvement, poorer prognosis, and greater recurrence and mortality risk in breast cancer has also been reported (58) . In hepatocellular carcinoma, hPRL expression was shown to be upregulated and positively correlated with tumor size, grade, and poorer survival (9) . The same study also demonstrated that hPRL enhanced the oncogenicity of hepatocellular carcinoma cell lines (9) . In addition to enhancing the oncogenicity of EC cells, we have demonstrated that autocrine hPRL decreases the sensitivity of EC cells to doxorubicin and paclitaxel both in vitro and in vivo. It has been previously observed that hPRL protects EC cells from cisplatin-stimulated apoptosis (5). hPRL has consistently been associated with reduced chemosensitivity in other cancers (15) (16) (17) . Exogenously administered hPRL reduced the sensitivity of breast cancer cells to different chemotherapeutic agents, including cisplatin, doxorubicin, Taxol, and vinblastine (18) . hPRL-stimulated cisplatin resistance is dependent on increased expression and activation of glutathione-S-transferase in breast cancer cells (18) . Glutathione S-transferase conjugates cisplatin to glutathione, resulting in the export of cisplatin from cells and, thus, preventing cisplatin from interacting and causing damage to DNA (17, 18) . Another hPRL-stimulated chemoresistance mechanism proposed involves the modulation of the levels of BCL-2 family proteins (17, 18) . Elevated levels of BCL-2 has been reported to be critical in promoting chemotherapeutic resistance in human cancers (59) . hPRL treatment increased antiapoptotic BCL-2 levels and decreased proapoptotic BAX levels in breast cancer cells, and the hPRL antagonist hPRL-G129R increased the BAX/ BCL-2 ratio (60, 61). In our study, BCL-2 mRNA was also dramatically increased by forced expression of hPRL in EC cells. Similarly, hPRL inhibited cisplatin-stimulated apoptosis in ovarian carcinoma cells (62) . Furthermore, an hPRL antagonist or a PRLR antagonist was shown to act synergistically with chemotherapeutic agents to induce breast cancer cell apoptosis (63, 64) . Clinically, higher serum hPRL levels were associated with poorer response to docetaxel (Taxotere) (65) , and the antiprolactinemic drug bromocriptine increased the efficacy of docetaxel (Taxotere) in metastatic breast cancer patients (19) .
CD24 is a hPRL-regulated gene (28) , and its expression was increased in EC cells with forced expression of hPRL. We previously reported that another growth factor, artemin, enhanced oncogenicity and reduced the chemosensitivity of EC cells in a CD24-dependent manner (4). Furthermore, CD24-positive EC cells exhibited increased cisplatin resistance compared with their CD24-negative counterparts both in vitro and in vivo (66) . CD24 was demonstrated to be involved in the accumulation of phosphorylated MET at the cell membrane through the formation of caveolin-1-enriched lipid rafts (66) . The resulting amplification of MET signaling transcriptionally upregulated the ABC transporters, leading to increased drug efflux and chemoresistance of the EC cells (66) . In the present study, we further observed that the hPRL-induced decrease in chemosensitivity of EC cells is CD24 dependent. Several cell cycle progression genes, such as CCND1, CCNE1, and CDK2, antiapoptotic genes, such as BCL-2 and BCL2L1, and signal transduction molecules, such as AKT1, ERBB2, MAP2K1, and MYC, which were previously observed to be increased by forced expression of CD24 in EC cells, were also upregulated by forced expression of hPRL in EC cells (12) . Likewise, in breast cancer, a negative correlation between CD24 expression and pathological response rate to neoadjuvant chemotherapy was reported (67) . It was postulated that CD24 interaction with the extracellular matrix might be implicated in chemotherapy resistance (67) . Another study has similarly reported that the CD24-negative phenotype is associated with improved survival in invasive ductal breast cancer patients treated with anthracyclines and/or taxanes (68) . These studies investigated the effect of CD24 expression independently of CD44 status, which likely accounted for the paradox that the CD44 high /CD24 low breast cancer stem cells are relatively refractory to chemotherapeutic agents. Furthermore, in hepatocellular carcinoma, CD24 expression is upregulated in chemoresistant tumors and CD24
+ hepatocellular carcinoma cells are associated with hepatic cancer stem cells (69) . Similarly, CD24 + ovarian cancer cells, which possess cancer stem cell-like properties, exhibited resistance toward antitumor drugs cisplatin and doxorubicin (27) .
In conclusion, our findings indicate that autocrine hPRL plays an important role in EC progression and metastasis and reduces the efficacy of chemotherapeutic agents in EC. Therefore, targeting PRL/PRLR signaling combined with chemotherapy can potentially improve the chemotherapeutic response and would constitute a therapeutic regimen in the treatment of late-stage EC. Inhibitors of PRL/PRLR signaling such as hPRLR antagonists (G129R-hPRL) and D1-9-G129R-hPRL (70) or a monoclonal antibody against hPRLR (LFA102) (71) could be considered as viable adjuvant therapy in late-stage EC (72) .
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